why choose us

First received: October 06, 2023

Clinical Trial: Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Hypophosphatasia

Study Type: INTERVENTIONAL


Official Title: A Phase 3, Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN1850 Versus Placebo Administered Subcutaneously in Pediatric (2 to < 12 Years of

Brief Summary: The primary purpose of this study is to evaluate the efficacy of ALXN1850 versus placebo on radiographic outcomes in pediatric participants with HPP who have not previously been treated with asfotase alfa.

Read more